Pipeline and clinical programs for neurological disorders
PUR001A
Neurological Indications (use case IP & formulation IP)
Psychedelic based therapeutics have been studied extensively in various neurological indications, with focuses on the mental health illness such as depression and pain. Our natural formulation of psychedelic will follow FDA’s botanical drug guidelines and be investigated in patients to treat the symptoms in traumatic brain injury (TBI), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Investigational new drug (IND) filling is planned in the second half of 2023.
PUR001B
Clinical study in neuroplasticity and neurogenesis (formulation IP)
Growing evidence have shown that when certain psychoactive compounds are administered, it can stimulate neurogenesis acutely and followed by molecular plasticity. Our scheduled clinical study is aiming to investigate neuroplasticity induced by psychedelics, and evaluate the impact to patients with acute brain injury and early on-set of neurodegenerative diseases. Study application is expected to be submitted in first half of 2024.
PUR002
Novel combinatorial synergistic therapy (combination IP)
In our pursuit of combinatorial and synergistic therapy for better efficacy in treatment of neurological patients, we are developing innovative therapeutics that combines proven mechanism of actions with new discoveries in psychoplastogens and their ability to promote neuroplasticity and neuro-rejuvenation. Intended for stroke and Parkinson's disease, the study application is expected to be submitted in the first half of 2024.
